References
- Cassidy J, Twelves C, Van Cutsem E, Hoff P, Boyer M, Bugat R, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566–75
- Roche: Xeloda (capecitabine) Investigator's Brochure 2005.
- Couch LS, Groteluschen DL, Stewart JA, Mulkerin DL. Capecitabine-related neurotoxicity presenting as trismus. Clin Colorectal Cancer 2003; 3: 121–3
- Niemann B, Rochlitz C, Herrmann R, Pless M. Toxic encephalopathy induced by capecitabine. Oncology 2004; 66: 331–5
- Formica V, Leary A, Cunningham D, Chua YJ. 5-Fluorouracil can cross brain-blood barrier and cause encephalopathy: Should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma. Cancer Chemother Pharmacol 2006; 58: 276–8
- Videnovic A, Semenov I, Chua-Adajar R, Baddi L, Blumenthal DT, Beck AC, et al. Capecitabine-induced multifocal leukoencephalopathy: A report of five cases. Neurology 2005; 65: 1792–4
- Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000; 34: 35–8
- Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L, Silingardi V. Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinomal. Ann Oncol 1996; 7: 412–5
- Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, et al. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol 1992; 31: 262–7
- Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1999. Neurologic disorder in a 65-year-old man after treatment of colon cancer. N Eng J Med 1999;341:512–9.
- Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996; 2: 477–81
- Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006; 12: 5496–502
- Ekenel M, Hormigo AM, Peak S, DeAngelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007 Jul 5; (Epub ahead of print).
- Bourke RS, et al. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973; 33: 1735–46
- Mata JF, Garcia-Manteiga JM, Lostao MP, Fernandez-Veledo S, Guillen-Gomez E, Larrayoz IM, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol 2001; 59: 1542–8
- Mackey JR, Yao SYM, Smith KM, Karpinski E, Baldwin SA, Cass CE, et al. Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999; 91: 1876–81